TFFP News and Press, TFF Pharmaceuticals Inc - Ordinary Shares From 03/10/21

Reports positive Phase 1 study results for Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder Awarded subcontract license by U.S. government agency to formulate biologic countermeasures to be used by the U.S. military Announces feasibility agreements with ...

NeuroRx and TFF Pharmaceuticals ([[TFFP]] +8.2%) are announcing that the companies have entered into a feasibility and material transfer agreement.Under the agreement, NeuroRx is delivering ZYESAMI™ materials to TFF in order to perform feasibility formulation work and testing.The ...

Feasibility work underway to determine the compatibility of NeuroRx’s ZYESAMI™ (aviptadil, synthetic VIP) as a dry powder formulation using TFF’s Thin-Film Freezing technology Dry powder inhalation technology has the potential to deliver ZYESAMI directly t...

Feasibility arrangement to test GreenLight Bioscience Inc’s COVID-19 messenger RNA vaccine candidate as a shelf-stable dry powder formulation using TFF Pharmaceuticals' Thin-Film Freezing technology. An easily reconstituted and shelf-stable dry powder formulation of mes...

Feasibility Arrangement for shelf-stable powder form of messenger RNA COVID-19 Vaccine Candidate announced by GreenLight Biosciences and TFF Pharmaceuticals -- Feasibility Arrangement to test GreenLight Bioscience Inc's COVID-19 messenger RNA vaccine candidate as a shelf-stable ...

On-demand presentations scheduled at H.C. Wainwright Global Life Sciences Conference and 33 rd Annual ROTH Conference Live panel discussion scheduled for March 15 th at 12pm ET TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical compa...

TFF Pharmaceuticals ([[TFFP]] -9.4%) says its Phase 1 trial for Voriconazole inhalation powder for the treatment of invasive pulmonary aspergillosis has successfully concluded.Data from the single ascending dose has indicated that doses of 10, 20, 40, and 80 mg could be delivered tw...

Phase 1 clinical study report for Voriconazole Inhalation Powder indicated no treatment emergent adverse events at peak plasma levels for Invasive Pulmonary Aspergillosis Phase 1 Single Ascending Dose study of Tacrolimus Inhalation Powder met and exceeded therapeutic drug ...

Company conference call and webcast at 4:30 PM ET TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today...

TFF Pharmaceuticals (TFFP) announces that the company obtained positive preclinical in vitro efficacy data regarding the thin film freezing ("TFF") formulated biodefense countermeasures.The studies were conducted in collaboration with the United States Army Medical Research Institut...